JP2019518721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518721A5 JP2019518721A5 JP2018554645A JP2018554645A JP2019518721A5 JP 2019518721 A5 JP2019518721 A5 JP 2019518721A5 JP 2018554645 A JP2018554645 A JP 2018554645A JP 2018554645 A JP2018554645 A JP 2018554645A JP 2019518721 A5 JP2019518721 A5 JP 2019518721A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- seq
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 210000000822 natural killer cell Anatomy 0.000 claims 6
- 102100024152 Cadherin-17 Human genes 0.000 claims 5
- 101710196881 Cadherin-17 Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 claims 1
- WMAXWOOEPJQXEB-UHFFFAOYSA-N 2-phenyl-5-(4-phenylphenyl)-1,3,4-oxadiazole Chemical compound C1=CC=CC=C1C1=NN=C(C=2C=CC(=CC=2)C=2C=CC=CC=2)O1 WMAXWOOEPJQXEB-UHFFFAOYSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108010027164 Amanitins Proteins 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 claims 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 229930126263 Maytansine Natural products 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- CIORWBWIBBPXCG-JZTFPUPKSA-N amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 108010052754 interleukin-14 receptor Proteins 0.000 claims 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 1
- 210000001324 spliceosome Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021179905A JP7275232B2 (ja) | 2016-01-09 | 2021-11-04 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276855P | 2016-01-09 | 2016-01-09 | |
| US62/276,855 | 2016-01-09 | ||
| PCT/US2017/012648 WO2017120557A1 (en) | 2016-01-09 | 2017-01-07 | Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179905A Division JP7275232B2 (ja) | 2016-01-09 | 2021-11-04 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518721A JP2019518721A (ja) | 2019-07-04 |
| JP2019518721A5 true JP2019518721A5 (enExample) | 2020-02-20 |
| JP6974348B2 JP6974348B2 (ja) | 2021-12-01 |
Family
ID=59274048
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554645A Active JP6974348B2 (ja) | 2016-01-09 | 2017-01-07 | がん処置のためのカドヘリン−１７特異的抗体及び細胞傷害性細胞 |
| JP2021179905A Active JP7275232B2 (ja) | 2016-01-09 | 2021-11-04 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
| JP2023075948A Active JP7482287B2 (ja) | 2016-01-09 | 2023-05-02 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179905A Active JP7275232B2 (ja) | 2016-01-09 | 2021-11-04 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
| JP2023075948A Active JP7482287B2 (ja) | 2016-01-09 | 2023-05-02 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11207419B2 (enExample) |
| EP (1) | EP3400013A4 (enExample) |
| JP (3) | JP6974348B2 (enExample) |
| KR (1) | KR20180127966A (enExample) |
| CN (4) | CN113817060B (enExample) |
| AU (1) | AU2017206089B2 (enExample) |
| IL (1) | IL260474B (enExample) |
| WO (1) | WO2017120557A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210116456A1 (en) * | 2018-05-16 | 2021-04-22 | Arbele Limited | Compositions and methods for diagnosis and treatment of cancer |
| US20210115152A1 (en) * | 2018-05-16 | 2021-04-22 | Arbele Limited | Composition of bispecific antibodies and method of use thereof |
| CN113891718B (zh) * | 2019-02-21 | 2025-01-28 | 杭州天康麦生物技术有限公司 | 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞 |
| TWI717880B (zh) | 2019-10-24 | 2021-02-01 | 中國醫藥大學附設醫院 | Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| CN114786720B (zh) * | 2019-12-05 | 2025-08-22 | 艾贝乐医药科技有限公司 | TriAx抗体的组合物及其制备和使用方法 |
| US12275798B2 (en) | 2021-06-17 | 2025-04-15 | Boehringer Ingelheim International Gmbh | Tri-specific binding molecules |
| EP4413366A4 (en) * | 2021-10-08 | 2025-09-10 | Tiberias Tech Hk Limited | TIBTECH METHODS AND COMPOSITIONS FOR THE DETECTION OF CDH17 |
| CA3240301A1 (en) * | 2021-12-07 | 2023-06-15 | Dennis Slamon | Cdh17 antibodies and methods of treating cancer |
| CN113999308B (zh) * | 2021-12-30 | 2022-03-11 | 深圳市人民医院 | 靶向钙粘蛋白17的纳米抗体及其应用 |
| EP4615870A1 (en) | 2022-11-11 | 2025-09-17 | Ospedale San Raffaele S.r.l. | Cdh17 car |
| WO2024175093A1 (en) * | 2023-02-23 | 2024-08-29 | Hansoh Bio Llc | Antibodies, antigen-binding fragments and methods of use |
| WO2024220437A2 (en) * | 2023-04-17 | 2024-10-24 | Arbele Limited | Compositions and methods for determining the effects of t cell engager |
| TW202509083A (zh) * | 2023-05-24 | 2025-03-01 | 大陸商普眾發現醫藥科技（上海）有限公司 | 抗體及其抗體－藥物偶聯物 |
| TW202517672A (zh) * | 2023-09-22 | 2025-05-01 | 大陸商樂普生物科技股份有限公司 | 抗ｃｄｈ１７抗體及其用途 |
| CN120230211A (zh) * | 2023-12-29 | 2025-07-01 | 广东菲鹏制药股份有限公司 | 抗cdh17抗体或其抗原结合片段及其应用 |
| WO2025242099A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 针对cdh17的抗体偶联药物及其用途 |
| WO2025242100A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 针对cdh17的抗体及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP4754219B2 (ja) * | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| AU2007332473B2 (en) * | 2006-12-14 | 2012-09-27 | Forerunner Pharma Research Co., Ltd. | Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same |
| CA2714413C (en) | 2008-02-08 | 2017-01-24 | Immunas Pharma, Inc. | Antibody capable of binding specifically to ab-oligomer, and use thereof |
| RU2011103199A (ru) * | 2008-06-30 | 2012-08-10 | Онкотерапи Сайенс, Инк. (Jp) | Антитела против cdh3, меченные радиоизотопной меткой, и их применение |
| US9207242B2 (en) * | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
| US9181339B2 (en) * | 2009-04-20 | 2015-11-10 | Oxford Bio Therapeutics Ltd. | Antibodies specific to cadherin-17 |
| BR112012020116B8 (pt) * | 2010-02-10 | 2023-01-10 | Perseus Proteomics Inc | Anticorpo anti-p-caderina marcado com metal radioativo, agente terapêutico contra o câncer e agente de diagnóstico de câncer que compreendem o dito anticorpo, hibridoma, bem como usos do mesmo para produzir um agente terapêutico contra o câncer e um agente de diagnóstico de câncer |
| BR112013001062A2 (pt) * | 2010-07-15 | 2016-05-24 | Synovex Corp | anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados |
| US20130259878A1 (en) * | 2010-10-20 | 2013-10-03 | Oxford Biotherapeutics Ltd | Antibodies |
| EP2710042A2 (en) * | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| ES2728936T3 (es) * | 2013-01-25 | 2019-10-29 | Amgen Inc | Anticuerpos dirigidos contra CDH19 para melanoma |
| JO3519B1 (ar) * | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| KR102357961B1 (ko) * | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
-
2017
- 2017-01-07 CN CN202111238485.4A patent/CN113817060B/zh active Active
- 2017-01-07 CN CN202111238201.1A patent/CN113817059B/zh active Active
- 2017-01-07 KR KR1020187023033A patent/KR20180127966A/ko not_active Ceased
- 2017-01-07 EP EP17736491.6A patent/EP3400013A4/en active Pending
- 2017-01-07 US US16/068,665 patent/US11207419B2/en active Active
- 2017-01-07 WO PCT/US2017/012648 patent/WO2017120557A1/en not_active Ceased
- 2017-01-07 JP JP2018554645A patent/JP6974348B2/ja active Active
- 2017-01-07 CN CN202111238599.9A patent/CN113912725B/zh active Active
- 2017-01-07 AU AU2017206089A patent/AU2017206089B2/en active Active
- 2017-01-07 CN CN201780005758.6A patent/CN108778327B/zh active Active
-
2018
- 2018-07-08 IL IL260474A patent/IL260474B/en active IP Right Grant
-
2021
- 2021-11-04 JP JP2021179905A patent/JP7275232B2/ja active Active
-
2023
- 2023-05-02 JP JP2023075948A patent/JP7482287B2/ja active Active